Abstract: A method for the preparation of synthetic peptide products containing up to about forty amino acid residues as ubiquitin-carboxyl terminal extensions expressed in procaryotic cells such as E. coli is disclosed. This is accomplished by cloning appropriate oligonucleotides encoding the desired peptide as a ubiquitin peptide extension gene, splicing the gene into an appropriate plasmid which, in turn is transformed into E. coli, or other appropriate procaryotic cells and inducing expression of the ubiquitin peptide fusion product. When expressed, the cells produce recoverable amounts of ubiquitin extended at its carboxyl terminus by the encoded carboxyl terminal extended peptide (CTEP). The peptide can be recovered as ubiquitin fused extension products (Ub-CTEP) or, alternatively, can be cleaved from the ubiquitin by an appropriate eucaryotic peptidase and purified.
Type:
Grant
Filed:
April 3, 1992
Date of Patent:
April 15, 1997
Assignee:
The University of Utah
Inventors:
Martin C. Rechsteiner, Yung Yoo, Keith D. Wilkinson, Kevin V. Rote
Abstract: The present invention is directed to recombinant the IL-21R.beta. chain or fragments thereof, cDNA coding therefore, vectors containing said cDNA, hosts transfected by said vectors, and monoclonal antibodies to said recombinant IL-2R.beta. or fragments thereof.
Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
Type:
Grant
Filed:
July 12, 1993
Date of Patent:
September 27, 1994
Assignee:
Immunex Corporation
Inventors:
John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower